Find comprehensive information on Ovarian Carcinoma, including clinical documentation, medical coding, ICD-10 codes, SNOMED CT codes, diagnosis codes, treatment protocols, staging, pathology reports, and healthcare guidelines. Learn about risk factors, symptoms, and diagnostic criteria for ovarian cancer. Explore resources for medical professionals, patients, and caregivers seeking accurate and reliable information on ovarian carcinoma management and coding best practices.
Also known as
Malignant neoplasm of ovary
Cancers specifically originating in the ovary.
Secondary malignant neoplasm of ovary
Cancer that has spread to the ovary from another site.
Malignant neoplasm without specification of site
Unspecified or unknown primary cancer location, possibly including ovary.
Personal history of malignant neoplasm of ovary
Indicates a past diagnosis of ovarian cancer, now in remission or treated.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the ovarian carcinoma primary?
Yes
Laterality specified?
No
Is it metastatic to ovary?
When to use each related code
| Description |
|---|
| Ovarian cancer |
| Ovarian cyst |
| Fallopian tube cancer |
Incomplete documentation of laterality (right, left, bilateral) for ovarian carcinoma can lead to coding errors and claim rejections.
Lack of specific histology documentation may result in inaccurate coding of the ovarian carcinoma type, impacting reimbursement and treatment planning.
Inconsistent or missing documentation of the cancer stage (I-IV) can cause incorrect coding, affecting quality reporting and resource allocation.
Q: What are the most effective current treatment strategies for advanced high-grade serous ovarian carcinoma recurring after first-line platinum-based chemotherapy?
A: Managing recurrent high-grade serous ovarian carcinoma (HGSOC) after platinum-based chemotherapy requires a tailored approach based on platinum-free interval. For platinum-sensitive recurrence (PFI > 6 months), reintroducing platinum-based chemotherapy in combination with bevacizumab, a PARP inhibitor like olaparib or niraparib, or other targeted therapies is generally recommended. In platinum-resistant disease (PFI < 6 months), options include single-agent chemotherapy (e.g., paclitaxel, docetaxel, pegylated liposomal doxorubicin), bevacizumab, PARP inhibitors for patients with BRCA mutations or other homologous recombination deficiencies, or clinical trial enrollment. Emerging therapies such as antibody-drug conjugates and immune checkpoint inhibitors are also being explored. Consider implementing molecular profiling to guide treatment decisions and identify potential targets for personalized therapy. Explore how S10.AI can help you stay updated on the latest clinical trial data and treatment guidelines for recurrent ovarian carcinoma.
Q: How can I differentiate between benign adnexal masses and early-stage ovarian carcinoma using imaging and CA-125 levels, and when is surgical intervention warranted?
A: Differentiating benign adnexal masses from early-stage ovarian carcinoma can be challenging. While transvaginal ultrasound and CA-125 levels are commonly used, their sensitivity and specificity are not absolute. Features suggestive of malignancy on ultrasound include solid components, thick septations, papillary projections, ascites, and increased vascularity. An elevated CA-125 level raises suspicion, but it can also be elevated in benign conditions. The Risk of Malignancy Index (RMI) combines ultrasound findings, menopausal status, and CA-125 to estimate risk. For high RMI scores or persistent suspicion despite negative initial workup, further imaging (e.g., MRI) or surgical consultation is recommended. Minimally invasive surgery (laparoscopy) allows for both diagnosis and potential treatment if malignancy is confirmed. Learn more about the latest advancements in ovarian cancer diagnostics and explore how S10.AI can assist in risk stratification and treatment planning.
Patient presents with signs and symptoms suggestive of ovarian carcinoma. Presenting complaints may include abdominal pain, bloating, pelvic pressure, early satiety, urinary frequency or urgency, and changes in bowel habits. Physical examination may reveal abdominal distension, ascites, palpable pelvic or abdominal mass, and tenderness. Differential diagnoses include benign ovarian cysts, uterine fibroids, endometriosis, pelvic inflammatory disease, and other gastrointestinal malignancies. Diagnostic workup may include pelvic ultrasound, CA-125 tumor marker, CT scan of the abdomen and pelvis, and other imaging studies as indicated. Biopsy and histopathological analysis are essential for definitive diagnosis of ovarian carcinoma, specifying histological subtype and grade. Staging of ovarian cancer is crucial for treatment planning and prognosis determination, often involving surgical staging procedures. Treatment options for ovarian carcinoma typically involve a multidisciplinary approach, including surgery (debulking, hysterectomy, salpingo-oophorectomy), chemotherapy (platinum-based regimens, targeted therapies), and potentially radiation therapy. Patient counseling regarding treatment options, potential side effects, and prognosis is essential. Follow-up care includes monitoring for recurrence, managing treatment-related complications, and providing supportive care. ICD-10 code C56.9 (Malignant neoplasm of ovary, unspecified) or more specific codes as determined by histology and staging are used for medical billing and coding. Referral to a gynecologic oncologist is standard practice for the management of ovarian carcinoma. Patient education regarding ovarian cancer symptoms, risk factors, and prevention strategies is crucial.